London International Avanti polyurethane condom: expanded labeling awaits publication of NICHD study.
This article was originally published in The Gray Sheet
Executive SummaryLONDON INTERNATIONAL'S MALE POLYURETHANE CONDOM LABELING CHANGES await publication of a study just completed by the National Institute of Child Health and Human Development (NICHD), the company says. The study, which evaluated the effectiveness of London International's Avanti thin and super-thin male polyurethane condoms in preventing pregnancy, is likely to be published this year in a peer review journal. London International believes that the study will support pregnancy and sexually transmitted disease claims for the condom.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.